ONCIMMUNE LEADING EARLY CANCER DETECTION
 
ONCIMMUNE LEADING EARLY CANCER DETECTION

EarlyCDT®-Liver is a simple blood test to aid detection and confirmation of HCC (hepatocellular carcinoma), in association with imaging, in high-risk patients with liver lesions of all sizes

  • EarlyCDT-Liver is complementary to imaging for the diagnosis of HCC. The very high specificity of the test makes it a clinically useful “confirmation” test
  • EarlyCDT-Liver detects HCC at all stages1, with similar performance across all stages
  • It’s high specificity for early stage HCC (BCLC 0-B) can accelerate treatment and deliver improved patient outcomes
  • The test complements all imaging modalities, providing confirmatory data

For nodules assessed by ultrasound alone, a High positive EarlyCDT-Liver test result increases the risk of HCC by three to six times dependent on initial risk.

Make EarlyCDT-Liver part of your workup of liver nodule malignancy risk assessment, and to detect cancers in surveillance more quickly.

Results are reported as High, Moderate or No Significant Level of Biomarkers detected. Only High and Moderate results are clinically actionable. The test rules-in, and does not rule-out, for HCC in liver lesions.

1 Macdonald I et al. Development and Validation of an ELISA test detecting a panel of Autoantibodies in combination with AFP for Early Detection of Hepatocellular Carcinoma.

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept